Focused Wealth Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Focused Wealth Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-7	Closed	–	–	774
2019 Q1	$0	Hold	7	–	–	﹤0.01%	738
2018 Q4	$0	Hold	7	–	–	﹤0.01%	730
2018 Q3	$0	Hold	7	–	–	﹤0.01%	692
2018 Q2	$0	Hold	7	–	–	﹤0.01%	714
2018 Q1	$0	Hold	7	–	–	﹤0.01%	724
2017 Q4	$0	Hold	7	–	–	﹤0.01%	720
2017 Q3	$0	Hold	7	–	–	﹤0.01%	700
2017 Q2	$0	Buy	+7	New	+$108	﹤0.01%	727
2016 Q4	–	Sell	-7	Closed	–	–	718
2016 Q3	$0	Hold	7	–	–	﹤0.01%	686
2016 Q2	$0	Hold	7	–	–	﹤0.01%	701
2016 Q1	$0	Hold	7	–	–	﹤0.01%	695
2015 Q4	$0	Hold	7	–	–	﹤0.01%	702
2015 Q3	$0	Hold	7	–	–	﹤0.01%	701
2015 Q2	$0	Hold	7	–	–	﹤0.01%	682
2015 Q1	$0	Hold	7	–	–	﹤0.01%	691
2014 Q4	$0	Hold	7	–	–	﹤0.01%	685
2014 Q3	$0	Hold	7	–	–	﹤0.01%	700
2014 Q2	$0	Buy	+7	New	+$75	﹤0.01%	681

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Focused Wealth Management's LXRX Position: Q2 2019 in Review

Focused Wealth Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2019, closing a stake of 7 shares.

Focused Wealth Management first reported a position in LXRX in Q2 2014 and held it in 18 quarters. The position peaked at $0 in Q1 2019. 109 funds tracked by Wall St. Rank hold LXRX as of Q2 2019.

Focused Wealth Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Focused Wealth Management sold 7 Lexicon Pharmaceuticals shares in Q2 2019.
Focused Wealth Management first reported a position in Lexicon Pharmaceuticals in Q2 2014 and held it in 18 quarters.
Focused Wealth Management's Lexicon Pharmaceuticals position peaked at $0 in Q1 2019.
109 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2019.

Based on Focused Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.